Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Gallium Maltolate for Recurrent Glioblastoma
NCT07515924Phase 1Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Mar 2027
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gallium maltolate in glioblastoma (GBM), sponsored by Medical College of Wisconsin. Primary endpoint: Glioma Tissue Difference at 3 months. Planned start Mar 2027; status: not yet recruiting.
02
Drugs
gallium maltolate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07515924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07515924.